2023
Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
Wang Y, Lu L, Ling C, Zhang P, Han R. Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors. Nutrients 2023, 15: 3984. PMID: 37764768, PMCID: PMC10537481, DOI: 10.3390/nu15183984.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-1/PD-L1 inhibitorsPD-L1 inhibitorsICI therapyDietary interventionBC patientsBreast cancerTherapeutic strategiesNovel immune checkpoint inhibitorsHDAC2 inhibitorsIntegrated therapeutic strategiesOptimal clinical benefitKaplan-Meier plotter platformNew therapeutic strategiesAnti-cancer effectsCheckpoint inhibitorsSupportive therapyClinical benefitHigh morbidityCombination therapyTreatment outcomesLethal malignancyTherapeutic effectEffective treatmentPrognostic analysisRandomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer
Cartmel B, Li F, Zhou Y, Gottlieb L, Lu L, Mszar R, Harrigan M, Ligibel J, Gogoi R, Schwartz P, Risch H, Irwin M. Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer. Cancer Medicine 2023, 12: 15492-15503. PMID: 37269192, PMCID: PMC10417064, DOI: 10.1002/cam4.6187.Peer-Reviewed Original ResearchConceptsExercise interventionOvarian cancerTrial of exerciseExercise-induced changesMin/weekGroup differencesSubset of participantsCause mortalityExercise groupOverall survivalStudy armsCA 125Randomized trialsBlood biomarkersBlood drawBreast cancerClinical significanceIGF-1Effect model analysisSecondary analysisBeneficial effectsCancerBiomarkersTrialsWomenDisparities in stage at diagnosis among breast cancer molecular subtypes in China
Zeng H, Wu S, Ma F, Ji J, Lu L, Ran X, Shi J, Li D, An L, Zheng R, Zhang S, Chen W, Wei W, He Y, He J. Disparities in stage at diagnosis among breast cancer molecular subtypes in China. Cancer Medicine 2023, 12: 10865-10876. PMID: 36951474, PMCID: PMC10225199, DOI: 10.1002/cam4.5792.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancerMolecular subtypesMass indexFamily historyFirst primary invasive breast cancerFirst primary breast cancerPrimary invasive breast cancerHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerBreast cancer molecular subtypesEnd Results (SEER) databaseBreast cancer treatment strategiesGrowth factor receptor 2Primary breast cancerInvasive breast cancerOverweight/obeseStage breast cancerBreast cancer patientsBreast cancer casesCancer molecular subtypesFactor receptor 2Cancer treatment strategiesMicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment
Zhou H, Jia W, Lu L, Han R. MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. Cancers 2023, 15: 824. PMID: 36765782, PMCID: PMC9913694, DOI: 10.3390/cancers15030824.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune checkpoint blockadeBreast cancerCheckpoint inhibitorsCheckpoint moleculesImmune checkpointsImmune checkpoint moleculesCancer-associated mortalityBreast cancer treatmentCommon cancer typesCombination regimenAdverse eventsCheckpoint blockadeClinical benefitTherapeutic effectTherapeutic candidateTherapeutic potentialCancer typesCancerCancer treatmentApplication of miRNAsTargetScan databaseMiRNA therapyTreatmentInhibitors
2022
Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
Han R, Yang H, Ling C, Lu L. Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor. Cancer Cell International 2022, 22: 368. PMID: 36424626, PMCID: PMC9685933, DOI: 10.1186/s12935-022-02786-6.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTNBC cellsBreast cancer treatmentNegative breast cancerCaspase-3 activity analysisExpression levelsSpheroid formation assayFurther RT-PCRTNBC patientsTumor burdenEarly recurrencePoor prognosisAggressive subtypeChemotherapy responseAlternative therapiesPreclinical studiesTNBC progressionMouse modelTherapeutic implicationsPreclinical experimentsSurvival rateTherapeutic useClinic practiceLevel assaysNeurospora crassa is a potential source of anti-cancer agents against breast cancer
Han R, Yang H, Ling C, Lu L. Neurospora crassa is a potential source of anti-cancer agents against breast cancer. Breast Cancer 2022, 29: 1032-1041. PMID: 35881300, DOI: 10.1007/s12282-022-01383-9.Peer-Reviewed Original ResearchConceptsBreast cancerT-47DBreast cancer stem cellsBreast cancer cell linesBreast cancer invasivenessCancer stem cell-related genesStem cell-related genesTumor cell proliferationCancer stem cellsMouse model resultsAnti-tumor agentsCell-related genesAnti-cancer agentsCancer cell linesTumor growthCancer invasivenessCancer stemCell proliferationMCF-10ACell linesCancerInhibition rateStem cellsSpheroid formationCASP3 activityImpact of a randomized weight loss trial on breast tissue markers in breast cancer survivors
Dieli-Conwright CM, Harrigan M, Cartmel B, Chagpar A, Bai Y, Li FY, Rimm DL, Pusztai L, Lu L, Sanft T, Irwin ML. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Npj Breast Cancer 2022, 8: 29. PMID: 35256599, PMCID: PMC8901848, DOI: 10.1038/s41523-022-00396-z.Peer-Reviewed Original ResearchBreast cancer survivorsWeight loss interventionBreast tissue biopsiesUsual careLoss interventionCancer survivorsWeight lossBreast cancerTissue markersTissue biopsiesLifestyle behavioural interventionUsual care groupSerum insulin levelsWeight loss trialWeight loss groupBreast cancer treatmentBreast tissue markersInsulin receptor levelsInflammatory markersAdiponectin levelsSerum leptinCare groupInsulin levelsSerum biomarkersBlood draw
2021
Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival
Li W, Amei A, Bui F, Norouzifar S, Lu L, Wang Z. Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival. Cancers 2021, 13: 2879. PMID: 34207556, PMCID: PMC8228363, DOI: 10.3390/cancers13122879.Peer-Reviewed Original ResearchT cell activationNeoantigen expressionChi-squared testOverall survivalBreast cancerMultivariable Cox proportional hazards modelsMultivariable Cox regression modelsCox proportional hazards modelImproved overall survivalT-cell statusT cell exhaustionBreast cancer patientsKaplan-Meier survivalBreast cancer survivalCox regression modelClinical-pathological variablesReceptor-positive subgroupCancer immunotherapy efficacyProportional hazards modelPearson's chi-squared testTumor-specific somatic mutationsSpearman correlation analysisImmunotherapy efficacyPathological variablesPatient survivalImpact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.
Dieli-Conwright C, Harrigan M, Cartmel B, Chagpar A, Bai Y, Rimm D, Pusztai L, Lu L, Sanft T, Irwin M. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Journal Of Clinical Oncology 2021, 39: e12501-e12501. DOI: 10.1200/jco.2021.39.15_suppl.e12501.Peer-Reviewed Original ResearchBreast cancer survivorsWeight loss interventionSerum insulin levelsCancer survivorsLoss interventionPercent body fatSerum levelsSerum biomarkersTissue biomarkersBody compositionMonth 6Insulin levelsBreast tissueBreast cancerInsulin receptorBody fatStage I breast cancerBreast tissue levelsI breast cancerWeight loss trialBreast tissue markersLevels of CD163Breast tissue biopsiesUsual careLifestyle interventionExamining the effect of obesity-associated gene variants on breast cancer survivors in a randomized weight loss intervention
Nguyen T, Irwin ML, Dewan AT, Cartmel B, Harrigan M, Ferrucci LM, Sanft T, Li F, Lu L, Salinas YD. Examining the effect of obesity-associated gene variants on breast cancer survivors in a randomized weight loss intervention. Breast Cancer Research And Treatment 2021, 187: 487-497. PMID: 33677781, DOI: 10.1007/s10549-021-06151-5.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsUsual care groupWeight loss interventionCancer survivorsLoss interventionCare groupFTO rs9939609Percent body fat changesWeight lossMeaningful weight lossBody fat changesBody mass indexObesity-associated gene FTOObesity-associated gene variantsPercent body fatGreater weight lossLifestyle interventionMass indexTreatment armsIntervention groupBreast cancerBody fatFat changesPurposeOur studyHealthy eating
2020
Regulation and characterization of tumor-infiltrating immune cells in breast cancer
Dai Q, Wu W, Amei A, Yan X, Lu L, Wang Z. Regulation and characterization of tumor-infiltrating immune cells in breast cancer. International Immunopharmacology 2020, 90: 107167. PMID: 33223469, PMCID: PMC7855363, DOI: 10.1016/j.intimp.2020.107167.Peer-Reviewed Original ResearchConceptsTumor-infiltrating immune cellsT cell activation statusImmune cellsCell activation statusT cell activationPatient survivalM2 macrophagesT cellsBreast cancerCell activationT cell peripheral toleranceTumor-infiltrating B cellsMultivariate Cox regression modelActivation statusBreast cancer patient survivalEffector T cellsT cell subsetsBreast cancer patientsImmune cell infiltrationAbundant plasma cellsCox regression modelKaplan-Meier survivalImmune cell typesMolecular pathwaysCancer patient survivalMeta-analysis of the clinicopathological significance of miRNA-145 in breast cancer
Lv P, Zhang Z, Hou L, Zhang Y, Lu L, Wang C, Shi F. Meta-analysis of the clinicopathological significance of miRNA-145 in breast cancer. Bioscience Reports 2020, 40: bsr20193974. PMID: 32869851, PMCID: PMC7502658, DOI: 10.1042/bsr20193974.Peer-Reviewed Original ResearchConceptsMiR-145 expressionBreast cancer patientsBreast cancerStandardized mean differenceBreast cancer tissuesAdjacent normal tissuesMiR-145Cancer patientsTumor suppressor miRNACancer tissuesLow expressionNormal tissuesLymph node metastasisUnfavorable prognostic factorLargest tumor diameterSuppressor miRNALower miR-145Normal breast tissueWeb of ScienceNode metastasisPrognostic factorsHealthy womenTumor diameterClinicopathological significanceEligible studiesInterplay of tRNA-Derived Fragments and T Cell Activation in Breast Cancer Patient Survival
Shan N, Li N, Dai Q, Hou L, Yan X, Amei A, Lu L, Wang Z. Interplay of tRNA-Derived Fragments and T Cell Activation in Breast Cancer Patient Survival. Cancers 2020, 12: 2230. PMID: 32785169, PMCID: PMC7466003, DOI: 10.3390/cancers12082230.Peer-Reviewed Original ResearchT cell activationBreast cancer patient survivalCancer patient survivalOverall survivalCell activationBreast cancerExpression of tRFsImproved survivalPatient survivalMultivariate Cox regression modelBreast cancer patientsCox regression modelKaplan-Meier survivalSpearman correlation analysisEffector CD8Cytotoxic functionCancer patientsExhaustion groupsTherapeutic targetCancer progressionCancerSurvivalGene co-expression network analysisActivation groupTRNA-derived fragmentsMicroRNA‑34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression.
Han R, Zhao J, Lu L. MicroRNA‑34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression. Oncology Reports 2020, 43: 2062-2072. PMID: 32186770, DOI: 10.3892/or.2020.7549.Peer-Reviewed Original ResearchConceptsBreast cancerNormal breast tissueMDA-MB-231 cellsPatient survivalT-47DKaplan-Meier survival curvesBreast tissueCancer-associated mortalityLonger survival timeCommon cancer typesExpression levelsReverse transcription-quantitative PCRPotential therapeutic toolBreast cancer invasionMicroRNA-34a expressionTranscription-quantitative PCRTumor cell proliferationOverall survivalUnderlying molecular mechanismsCaspase-3 activityDownregulation of E2F1Clinical managementExpression of E2F1Survival timeClinical relevance
2019
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer
Lu L, Huang H, Zhou J, Ma W, Mackay S, Wang Z. BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. BMC Cancer 2019, 19: 387. PMID: 31023256, PMCID: PMC6482542, DOI: 10.1186/s12885-019-5595-3.Peer-Reviewed Original ResearchConceptsT cell activation statusCell activation statusPatient survivalT cell activationBreast cancerActivation statusCCND1 levelsCell activationT cell activation scoreCCND1 expressionKaplan-Meier survival curvesAdjusted hazard ratioCCND1 expression levelsBreast cancer patient survivalImmune checkpoint blockadeBetter overall survivalBreast cancer patientsCox regression modelCancer patient survivalT cell recognitionBRCA1 levelsBRCA1 mRNA expressionCheckpoint blockadeHazard ratioOverall survival
2018
Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer
Chen Q, Yao L, Burner D, Minev B, Lu L, Wang M, Ma W. Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer. Clinical And Translational Oncology 2018, 21: 433-442. PMID: 30218306, DOI: 10.1007/s12094-018-1941-1.Peer-Reviewed Original ResearchConceptsEpithelial membrane protein-2MDA-MB-231 cellsBreast cancerBreast cancer cellsNovel biomarkersMCF7 cellsCancer cellsAnti-pan cytokeratinPrimary breast cancerBreast cancer patientsMesenchymal transition eventsPatient blood samplesTumor cell recoveryFlow cytometric assayCTC countCancer patientsHealthy donorsBlood samplesMembrane protein 2Cytometric assayTumor cellsEMP2 expressionCancerCell spikingBiomarkersRandomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study
Sanft T, Usiskin I, Harrigan M, Cartmel B, Lu L, Li FY, Zhou Y, Chagpar A, Ferrucci LM, Pusztai L, Irwin ML. Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. Breast Cancer Research And Treatment 2018, 172: 105-112. PMID: 30062572, DOI: 10.1007/s10549-018-4895-7.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsWeight loss interventionUsual care groupBody mass indexBreast cancer riskCancer survivorsUsual careLoss interventionBreast cancerStage 0Quantitative polymerase chain reactionCare groupTelomere lengthCancer riskStage II/III breast cancerObese breast cancer survivorsWeight lossI breast cancerNon-Hispanic whitesPurposeSome studiesMass indexIntervention groupPhysical activityBlood samplesConclusionOur findings
2017
Elevated T cell activation score is associated with improved survival of breast cancer
Lu L, Bai Y, Wang Z. Elevated T cell activation score is associated with improved survival of breast cancer. Breast Cancer Research And Treatment 2017, 164: 689-696. PMID: 28488141, DOI: 10.1007/s10549-017-4281-x.Peer-Reviewed Original ResearchConceptsT cell activation scoreBreast cancer patientsOverall survivalPatients' overall survivalCancer patientsImproved survivalPD-1Activation scoresBreast cancerCell death-1 receptorLow PD-1 expressionMultivariate Cox regression analysisT-lymphocyte antigen-4Kaplan-Meier survival curvesT cell activation statusDeath-1 receptorPD-1 expressionEffector T cellsImmune checkpoint blockadeCox regression analysisPoor overall survivalCox regression modelT cell functionActivation groupCell activation status
2015
DNA Repair Genes XRCC1 and ERCC1 Polymorphisms and the Risk of Sporadic Breast Cancer in Han Women in the Gansu Province of China
Zhu G, Wang L, Guo H, Lu L, Yang S, Wang T, Guo H, Wang H, Min J, Yang K, Chen X, Liu Y, Wang Z, Su H. DNA Repair Genes XRCC1 and ERCC1 Polymorphisms and the Risk of Sporadic Breast Cancer in Han Women in the Gansu Province of China. Genetic Testing And Molecular Biomarkers 2015, 19: 387-393. PMID: 25961110, DOI: 10.1089/gtmb.2015.0001.Peer-Reviewed Original ResearchConceptsBreast cancerSporadic breast cancerProgesterone receptorEstrogen receptorHan womenSingle nucleotide polymorphismsXRCC1 rs25487 polymorphismDisease-free controlsDNA repair gene XRCC1DNA damage repair genesBreast cancer susceptibilityRisk of diseaseDNA repair capacityERCC1 polymorphismsRs25487 polymorphismGG genotypeAA genotypeXRCC1 rs25487Significant associationDisease riskCancerGene XRCC1GC haplotypeCancer susceptibilityRepair capacityCirculating tumor cell clusters-associated gene plakoglobin and breast cancer survival
Lu L, Zeng H, Gu X, Ma W. Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival. Breast Cancer Research And Treatment 2015, 151: 491-500. PMID: 25957595, DOI: 10.1007/s10549-015-3416-1.Peer-Reviewed Original ResearchConceptsBreast cancer survivalCancer survivalBreast cancerTumor cellsDisease-specific deathBreast cancer recurrencePotential prognostic biomarkerBreast cancer metastasisEpithelial-mesenchymal transitionHigh metastatic potentialFurther metastasesPatient survivalCancer recurrencePrognostic biomarkerTherapeutic targetSurvival analysisMetastatic potentialCancer metastasisMajor causeHigh expressionEpithelial cellsCancerRole of plakoglobinDouble-edged functionSurvival